OR WAIT null SECS
June 17, 2022
Exothera, LogicBioTherapeutics, and Polyplus-transfection, are collaborating on the development of a scalable AAV manufacturing platform.
June 16, 2022
The new draft guidance describes a standards recognition program for regenerative medicine therapies.
The draft ICH Q9(R1) document details the importance of quality risk management principles.
June 13, 2022
Yourway intends to construct a new manufacturing facility in the Dublin Airport Logistics Park.
The deal will see Spectrum market and distribute ANGUS’ biologics grade buffers in the United States and Canada.
Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.
Moderna’s mRNA-1273.214 booster candidate exhibited an eight-fold boost in neutralizing geometric mean titers against Omicron.
REGENXBIO has opened a new in-house facility at its headquarters in Rockville, Md., that will be used to manufacture AAV gene therapies at commercial scale.
June 10, 2022
In the report, the agency presents the activities it accomplished in 2021 to protect and promote public health.
Astellas Pharma has opened its new gene therapy manufacturing facility in Sanford, NC, which will support clinical- and commercial-scale manufacturing of AAV vectors for gene therapies.